Icon Plc (NASDAQ:ICLR) – Analysts at KeyCorp dropped their Q1 2018 earnings per share (EPS) estimates for Icon in a research note issued to investors on Tuesday, according to Zacks Investment Research. KeyCorp analyst D. Hooker now expects that the medical research company will earn $1.40 per share for the quarter, down from their prior forecast of $1.42. KeyCorp has a “Buy” rating and a $130.00 price objective on the stock. KeyCorp also issued estimates for Icon’s Q3 2018 earnings at $1.55 EPS, Q4 2018 earnings at $1.61 EPS, FY2018 earnings at $6.02 EPS and FY2019 earnings at $6.98 EPS.
Several other research analysts have also commented on the stock. Mizuho set a $109.00 price target on shares of Icon and gave the stock a “hold” rating in a research note on Wednesday, January 24th. SunTrust Banks restated a “buy” rating and set a $133.00 price target on shares of Icon in a research note on Monday, January 22nd. Evercore ISI assumed coverage on shares of Icon in a research note on Thursday, January 18th. They set an “outperform” rating and a $126.00 price target on the stock. BidaskClub lowered shares of Icon from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 16th. Finally, Zacks Investment Research lowered shares of Icon from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Icon currently has an average rating of “Buy” and an average target price of $124.55.
Icon (ICLR) traded down $4.81 during trading on Thursday, reaching $106.93. 462,691 shares of the company’s stock traded hands, compared to its average volume of 291,584. Icon has a 1 year low of $76.46 and a 1 year high of $124.48. The firm has a market cap of $5,790.47, a price-to-earnings ratio of 20.72, a PEG ratio of 1.51 and a beta of 0.48. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. bought a new stake in shares of Icon during the 4th quarter worth $8,883,000. C M Bidwell & Associates Ltd. bought a new stake in shares of Icon during the 4th quarter worth $196,000. Aperio Group LLC boosted its holdings in shares of Icon by 4.6% during the 4th quarter. Aperio Group LLC now owns 15,640 shares of the medical research company’s stock worth $1,754,000 after buying an additional 682 shares during the period. Picton Mahoney Asset Management bought a new stake in shares of Icon during the 4th quarter worth $2,590,000. Finally, Boston Partners boosted its holdings in shares of Icon by 0.5% during the 4th quarter. Boston Partners now owns 1,111,725 shares of the medical research company’s stock worth $124,680,000 after buying an additional 5,314 shares during the period. 89.60% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “KeyCorp Weighs in on Icon Plc’s Q1 2018 Earnings (NASDAQ:ICLR)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/04/q1-2018-eps-estimates-for-icon-plc-reduced-by-analyst-iclr.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Get a free copy of the Zacks research report on Icon (ICLR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.